- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Economist Award for Bioscience Innovation Announced
13 October
J. Craig Venter has won this year's Economist Innovation Award for Bioscience. Dr Venter, president of the J. Craig Venter Institute (JCVI)(www.jcvi.org), Is to be honoured for his genomic research and its potential "to revolutionise personal medicine, pharmaceuticals and biofuels." At the forefront of genomic research for almost two decades, Dr Venter's discoveries have been said to open up the scientific research of the microbial world and how it affects humans.
Commenting on his award, Dr Venter said: "We are now in a world 100% dependent on scientific innovation. Innovation is the key driver for success, especially in challenging economic times."
The award will be presented at a ceremony at London's Science museum on October 29th. The Economist's Innovation Summit, focusing on the interface between innovation and business, will take place the following day.
For more information on the winner and the award, click here.
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
